Viracept
(Nelfinavir mesylate)PreclinicalSmall molecule
Nelfinavir mesylate is an antiviral medication used to treat HIV infection by helping to reduce the amount of HIV in the blood and slow down the progression of the disease.[1] Viracept is currently being investigated across 4 indications[3], with its most advanced program in Preclinical.[1]
Viracept is one of 174 small molecule programs targeting HIV infection. It is currently in Preclinical.
4
Indications
86
Total Trials
0
Active Trials
173
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
123 competitors in HIV Infection
#DrugCompanyPhaseTrials
1Niacor
AbbVieApproved
Soriatane
GSKApproved
Rifadin
SanofiApproved
Ninlaro
TakedaApproved
Tybost
GileadApproved
Neoral
NovartisApproved
Marinol
Jazz PharmaceuticalsApproved
Istodax
TevaApproved
Crestor
AstraZenecaApproved
Calciferol
Jazz PharmaceuticalsApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Effectiveness17 trials
Show 14 more trials
Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001091·200 enrolled
Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00006441·398 enrolled
Drug12 trials
A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000892·300 enrolled
Show 9 more trials
A Study to Compare Two Different Anti-HIV Drug Regimens
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000924·120 enrolled
The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00017758·56 enrolled
A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000912·475 enrolled
Treatment7 trials
Show 4 more trials
Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000903·444 enrolled
HIV infection7 trials
Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000872·55 enrolled
Show 4 more trials
A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000919·900 enrolled
33 more indications
Children3 trials
A Study to Compare Two Anti-HIV Combination Therapies Each Containing Saquinavir in HIV-Positive Children
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000913·50 enrolled
Pancreatic Cancer2 trials
Interaction2 trials
HIV-12 trials
Drug Therapy2 trials
A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000902·217 enrolled
Multiple Myeloma1 trial
Glioblastoma Multiforme1 trial
Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme
Terminated·—·Phase 1·NCT00915694·15 enrolled
Medication1 trial
A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001122·74 enrolled
Liposarcoma1 trial
Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma
Terminated·—·Phase 1/2·NCT00233948·29 enrolled
Drug Interactions1 trial
Kidney Disease1 trial
HIV-Infected Individuals1 trial
A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000859·1,300 enrolled
Intensive Care1 trial
Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00028327·250 enrolled
Mycobacterium avium complex disease1 trial
Hematologic Cancer1 trial
Lipodystrophy1 trial
Combination Therapy1 trial
Kidney Cancer1 trial
Non-Small Cell Lung Cancer1 trial
Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Completed·—·Phase 1/2·NCT00589056·55 enrolled
Double-blind1 trial
Progesterone1 trial
Randomized1 trial
Safety and Efficacy1 trial
Chemotherapy1 trial
A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000899·10 enrolled
Tuberculosis1 trial
Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00004736·44 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nelfinavir mesylate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Human Immunodeficiency Virus Type 1 Protease Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- AAgouron Pharmaceuticals